儿童院内心搏骤停后的治疗性低温
该试验在37家儿童医院开展,纳入院内心搏骤停后恢复循环6小时内、年龄大于48小时且小于18岁的昏迷患儿,随机分入治疗性低温组(目标温度33.0°C)或治疗性正常体温组(目标温度36.8°C)。因无效提前终止,共随机329例。在257例心搏骤停前VABS-II评分至少70分且可评估的患儿中,主要疗效终点(12个月生存且VABS-II评分≥70分)两组无显著差异(低温组36% vs 正常体温组39%;RR 0.92,95%CI 0.67–1.27;P=0.63)。1年生存率、神经行为功能变化、血制品使用、感染、严重不良事件及28天死亡率均无显著差异。
要点
- 昏迷儿童院内心搏骤停后,治疗性低温(33.0°C)与治疗性正常体温(36.8°C)相比,12个月生存且VABS-II评分≥70分的比例无显著差异(36% vs 39%;RR 0.92,95%CI 0.67–1.27;P=0.63)。
- 1年生存率两组无显著差异(低温组49% vs 正常体温组46%;RR 1.07,95%CI 0.85–1.34;P=0.56)。
- 神经行为功能(VABS-II评分从基线至12个月的变化)两组无显著差异(P=0.70)。
- 血制品使用、感染、严重不良事件及28天死亡率两组均无显著差异。
- 试验因无效提前终止,共随机329例。
适用人群与场景
- 院内心搏骤停后恢复循环的昏迷儿童,年龄大于48小时且小于18岁,在恢复循环6小时内随机分组。
- 主要疗效终点评估人群为心搏骤停前VABS-II评分至少70分的患儿。
诊断标准与关键阈值
- 主要疗效终点:心搏骤停后12个月生存且VABS-II评分≥70分(VABS-II评分范围20–160分,分数越高功能越好)。
处置流程与药物剂量
- 治疗性低温组:目标温度33.0°C。
- 治疗性正常体温组:目标温度36.8°C。
- 随机分组在恢复循环6小时内进行。
研究设计与关键结果
- 研究类型:在37家儿童医院开展的随机对照试验,因无效提前终止,共随机329例。
- 主要疗效终点:在257例心搏骤停前VABS-II评分至少70分且可评估的患儿中,低温组36%(48/133)vs 正常体温组39%(48/124),RR 0.92(95%CI 0.67–1.27),P=0.63。
- 1年生存率:在327例可评估患儿中,低温组49%(81/166)vs 正常体温组46%(74/161),RR 1.07(95%CI 0.85–1.34),P=0.56。
- 神经行为功能变化:在317例可评估患儿中,VABS-II评分从基线至12个月的变化两组无显著差异(P=0.70)。
- 不良事件:血制品使用、感染、严重不良事件及28天死亡率两组均无显著差异。
证据类型、等级与局限
- 证据类型:随机对照试验。
- 试验因无效提前终止。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:在院内心搏骤停后存活的昏迷儿童中,与治疗性正常体温相比,治疗性低温未在1年生存且功能良好方面带来显著获益。
指南或共识出处
- THAPCA-IH试验,ClinicalTrials.gov注册号NCT00880087,由美国国家心肺血液研究所资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Targeted temperature management is recommended for comatose adults and children after out-of-hospital cardiac arrest; however, data on temperature management after in-hospital cardiac arrest are limited.
METHODS: In a trial conducted at 37 children's hospitals, we compared two temperature interventions in children who had had in-hospital cardiac arrest. Within 6 hours after the return of circulation, comatose children older than 48 hours and younger than 18 years of age were randomly assigned to therapeutic hypothermia (target temperature, 33.0°C) or therapeutic normothermia (target temperature, 36.8°C). The primary efficacy outcome, survival at 12 months after cardiac arrest with a score of 70 or higher on the Vineland Adaptive Behavior Scales, second edition (VABS-II, on which scores range from 20 to 160, with higher scores indicating better function), was evaluated among patients who had had a VABS-II score of at least 70 before the cardiac arrest.
RESULTS: The trial was terminated because of futility after 329 patients had undergone randomization. Among the 257 patients who had a VABS-II score of at least 70 before cardiac arrest and who could be evaluated, the rate of the primary efficacy outcome did not differ significantly between the hypothermia group and the normothermia group (36% [48 of 133 patients] and 39% [48 of 124 patients], respectively; relative risk, 0.92; 95% confidence interval [CI], 0.67 to 1.27; P=0.63). Among 317 patients who could be evaluated for change in neurobehavioral function, the change in VABS-II score from baseline to 12 months did not differ significantly between the groups (P=0.70). Among 327 patients who could be evaluated for 1-year survival, the rate of 1-year survival did not differ significantly between the hypothermia group and the normothermia group (49% [81 of 166 patients] and 46% [74 of 161 patients], respectively; relative risk, 1.07; 95% CI, 0.85 to 1.34; P=0.56). The incidences of blood-product use, infection, and serious adverse events, as well as 28-day mortality, did not differ significantly between groups.
CONCLUSIONS: Among comatose children who survived in-hospital cardiac arrest, therapeutic hypothermia, as compared with therapeutic normothermia, did not confer a significant benefit in survival with a favorable functional outcome at 1 year. (Funded by the National Heart, Lung, and Blood Institute; THAPCA-IH ClinicalTrials.gov number, NCT00880087 .).
参考来源
- Moler FW, Silverstein FS, Holubkov R, et al. Therapeutic Hypothermia after In-Hospital Cardiac Arrest in Children. N Engl J Med. 2017. PMID: 28118559. doi:10.1056/NEJMoa1610493
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。